News

PV-10 is a proprietary, injectable formulation of Rose Bengal, a small molecule agent that has been in use for nearly 30 years by ophthalmologists to assess damage to

American Regent has initiated the voluntary recall because some vials of this lot were observed to be slightly discolored and upon standing have the appearance of sediment on

Celanese claims that VitalDose excipients are based on EVA polymers and offer a wide degree of flexibility in the design of transdermal, subcutaneous implant and mucosal insert dosage

Horizant, also referred to as GSK1838262/XP13512, is a patented new chemical entity. It is under review for the treatment of moderate-to-severe primary restless legs syndrome (RLS). FDA has

Vilazodone is a novel dual-acting modulator of serotonin neurotransmission in development for the treatment of major depressive disorder with the potential for follow-on indications including generalised anxiety disorder

Utilising CTMS as a centralised repository for all investigators, clinical trial sponsors can collect and track all relevant information about their investigators, from personal profiles to disease specialties,

Reportedly, a mean Progression Free Survival (PFS) of 11.7 months was observed among subjects achieving an OR. In the PV-10 Phase 2 trial, a complete response (CR) of

Mycofenolatmofetil Actavis (mycophenolate mofetil) is the generic equivalent of Roche’s Cellcept, and is used with other medicines to lower the body’s immunity after heart, kidney or liver transplant.

The original contract between Nordion (formerly MDS) and Capgemini was effective June 2006, and this current contract extension calls for Capgemini to continue to provide information technology (IT)